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Abstract
Nitric oxide (NO) plays important physiological roles in the vasculature to regulate angiogenesis, blood flow, and
hemostasis. In solid tumors, NO is generally acknowledged to mediate angiogenic responses to several growth
factors. This contrasts with conflicting evidence that NO can acutely increase tumor perfusion through local va-
sodilation or diminish perfusion by preferential relaxation of peripheral vascular beds outside the tumor. Because
thrombospondin 1 (TSP1) is an important physiological antagonist of NO in vascular cells, we examined whether,
in addition to inhibiting tumor angiogenesis, TSP1 can acutely regulate tumor blood flow. We assessed this activity
of TSP1 in the context of perfusion responses to NO as a vasodilator and epinephrine as a vasoconstrictor. Nitric
oxide treatment of wild type and TSP1 null mice decreased perfusion of a syngeneic melanoma, whereas epineph-
rine transiently increased tumor perfusion. Acute vasoactive responses were also independent of the level of tumor-
expressed TSP1 in a melanoma xenograft, but recovery of basal perfusion was modulated by TSP1 expression. In
contrast, overexpression of truncated TSP1 lacking part of its CD47 binding domain lacked this modulating activity.
These data indicate that TSP1 primarily regulates long-term vascular responses in tumors, in part, because the tumor
vasculature has a limited capacity to acutely respond to vasoactive agents.
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Introduction
Solid tumor growth requires the generation of new blood vessels
from an established vascular network, a process termed angiogenesis.
The newly formed vascular network provides necessary nutrients and
oxygen tomeet the increased metabolic demand of the growing tumor.
Tumor angiogenesis is an intensely pursued therapeutic target for treat-
ing cancers. Although several antiangiogenic drugs have attained US
Food and Drug Administration approval and significantly delay tumor
progression, hypertension is a frequent adverse effect of these agents
[1]. If arteries supplying the tumor are selectively constricted, this
adverse effect could contribute to the efficacy of antiangiogenic drugs.
If instead these drugs induce systemic hypertension, the resulting in-
creased tumor perfusion could limit their efficacy [2,3].
Although long-term control of angiogenesis can clearly limit tumor
growth, acute regulation of tumor blood flow and dynamics may be
more difficult. The intratumor vasculature is poorly organized, and
it displays variability in flow and tissue perfusion. Intratumoral vessels
typically lack anatomic elements required for normal vasoactive re-
sponses including autonomic neural elements [4]. Additionally, some
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tumors lack lymphatic vessels, which combined with increased vas-
cular permeability increases interstitial pressure and decreases tumor
perfusion [5]. Increased tumor interstitial pressure encourages vascular
and lymphatic collapse, stagnation, and reversal of arterial flow [5,6].
Consequently, tumor blood flow is very heterogeneous, with areas
of significant under perfusion and hypoxia [7]. Additionally, tumor
vessels display dynamic changes that are specific for the growth stage
of the tumor [8]. Such irregularity in flow confounds effective delivery
of therapeutic agents to tumor tissue [9,10]. In contrast, adjacent
blood vessels that feed tumor vessels do contain normal vascular anat-
omy and should respond to vasoactive challenges in a predictable fash-
ion. Limiting tumor perfusion with agents that can predictably
enhance or retard tumor blood flow represents a potential therapeutic
avenue [11,12]. An alternative strategy to acutely control flow using
agents that cause rapid tumor vascular thrombosis and obliteration
has also shown promise [13].
Nitric oxide (NO) is an important signaling molecule for acute
regulation of blood flow and for long-term angiogenic responses. It
is constantly produced by vascular cells, and it relaxes the arterial
component of blood vessels [14]. The direct effect of vessel relaxation
is to increase blood flow and tissue perfusion. Chronic exposure to
NO drives the formation of new blood vessels by stimulating both
endothelial and vascular smooth muscle cell (VSMC) proliferation
and migration as part of a physiologic response to normal wound
healing and during tumor growth and metastasis [15,16]. Further-
more, endogenous NO can be limiting for tumor blood flow [17].
Several studies have reported that inhibition of NO synthase using
either N -nitro-L-arginine methyl ester or N ω-nitro-L-arginine results
in decreased total tumor blood flow in animal models [18–22] or has
inhibitory effects on tumor growth [23]. These reports are supported
by studies demonstrating that tumor blood flow is increased by ex-
ogenous NO donors [24] (and reviewed in Refs. [25–27]). Other
studies, however, found that NO can decrease tumor blood flow in
animal models, which has been attributed to a steal effect [28].
Consistent with these conflicting studies in rodents, attempts to
demonstrate therapeutic responses through manipulation of tumor
blood flow have been modest in people [23,29–31]. Nonspecific in-
hibition of endogenous NO production in a recent phase I trial in
patients with several tumor types documented immediate decreases
in tumor blood volume using contrast-enhanced computed tomog-
raphy [30]. In some cases, tumor blood volume remained decreased
for 24 hours. In contrast, treatment of patients with hepatic tumors
using a continuous infusion of epinephrine increased tumor blood
flow in 66% of cases [32].
The matricellular protein thrombospondin 1 (TSP1) was the first
identified endogenous angiogenesis inhibitor [33,34]. Its expression
is frequently lost in some types of human tumors. Conversely, over-
expression of TSP1 in experimental tumors dramatically decreases
tumor growth rate, neovascularization, and metastasis [35]. Throm-
bospondin 1 inhibits NO signaling in both endothelial and VSMC
by inhibiting activation of soluble guanylyl cyclase (sGC) [15,36]. In
VSMC and in vivo, TSP1 limits vasorelaxation by NO [37]. Under
an ischemic stress, blocking TSP1 acutely increases tissue blood flow
and perfusion [37]. The ability of TSP1 to abrogate NO-stimulated
angiogenesis and blood flow changes requires the cell surface receptor
CD47 [36]. Targeting this receptor mimics the inhibitory actions of
TSP1 on NO-driven vascular responses [38].
Given the pivotal role that TSP1 plays in controlling NO-driven
vascular responses and blood flow in nontumor vascular networks,
we hypothesized that, in addition to its antiangiogenic activity,
TSP1 may acutely regulate flow in the peritumoral or tumoral vas-
culature. A recent histochemical analysis of pancreatic tumors in
mice treated with recombinant TSP1 type 1 repeats inferred that this
treatment decreased tumor blood flow [39], but a direct assessment
of flow was not performed. Here, we approach this question by as-
sessing the role of host and tumor TSP1 expression in regulating
acute tumor blood flow responses. We present evidence that vasoac-
tive agents such as NO and epinephrine primarily alter tumor perfu-
sion in an indirect manner. Thrombospondin 1 expressed in the
tumor vasculature does not alter such blood flow responses to vaso-
active stimuli. In contrast, overexpression of TSP1 by tumor cells
moderately decreases tumor blood flow responses to NO and epi-
nephrine. These results provide important insights for evaluating ef-
forts to directly alter tumor blood flow using vasoactive agents and
for maximizing the efficacy of angiogenesis inhibitors.
Materials and Methods
Animals
Wild type and TSP1 null C57BL/6mice were housed in a pathogen-
free environment and had ad libitum access to standard rat chow
and water. Cr(Cnr)athymic<nu>fBf female mice were obtained
from Charles River (Taconic, MD). Care and handling of animals
comply with standards established by the Animal Care and Use Com-
mittee of the National Cancer Institute.
Reagents and Cells
The murine B16F10 melanoma cell line was kindly provided by
Dr. Lyuba Varticovski. Cells were expanded in standard growth me-
dium (RPMI with 10% FCS; Gibco, Grand Island, NY) and frozen
at uniform passage for injection in mice. The human melanoma cell
line, MDA-MB-435, was previously transfected with a CMV-
THBS1 expression plasmid, and TSP1 expression was quantified as
described [40]. The parental cell line, a TSP1-overexpressing clone
(TH26) and a clone expressing a C-terminal truncation of TSP1
(TH50) were used. Cells were MAP tested and expanded in com-
plete DMEM containing 10% fetal bovine serum and 750 μg/ml
G418 (Gibco-BRL, Gaithersburg, MD) and frozen for future use.
Porcine femoral artery VSMC were harvested from Yucatan white
hairless miniature pigs and cultured in SM-GM +2.5% FCS (Lonza,
Belgium). Bovine aortic endothelial cells (BAECs) were prepared
from fresh aortic segments and grown in DMEM containing 10%
fetal bovine serum, penicillin G (100 units/ml), and streptomycin
(100 μg/ml).
Blood Oxygen Level–Dependent Magnetic Resonance Imaging
Magnetic resonance imaging (MRI) scans were acquired using a
4.7-T scanner (Bruker BioSpin, Karlsruhe, Germany) and isoflurane
anesthesia. Muscle and tumor tissue was scanned at rest, so altera-
tions in oxygenation reflected changes in perfusion rather than in ox-
ygen consumption. Magnetic resonance measurements were started
after the mouse’s body temperature reached 37°C. Before the ex-
periments, a multislice multiecho (MSME) sequence was used to de-
termine the target slice location. A series of T2*-weighted gradient
echo blood oxygenation level–dependent (BOLD) image data sets
transverse to the midpoint of the femur were repeatedly acquired
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Figure 1. NO-stimulated angiogenesis in B16F10 melanomas is inhibited by exogenous TSP1. B16F10 tumor biopsies (1 mm3) excised
from sex- and age-matched wild type and TSP1 null mice were embedded in three-dimensional collagen matrix and incubated in growth
medium±DETA/NO (10 μM) (A, left panel) or ± TSP1 (2.2 nM; A, right panel). Sex- and age-matched athymic nudemicewere injectedwith
equal numbers of control MDA-MB-435, clone TH26, or clone TH50 tumor cells to the lateral thigh. Tumor size was determined with cal-
ipers by the same examiner at the indicated time intervals, and volumes were calculated (B). Sex- and age-matched athymic nude mice
were injectedwith equal numbers ofMDA-MB-435, Neo vector-transfected, clone TH26, or clone TH50 cells to the lateral thigh. Equal sized
tumors were excised, and 1 mm3 biopsies were embedded in collagen matrix with growth medium ± NO (DETA/NO 10 μM) (C). After
7 days of incubation, vascular cell invasion was quantified as the distance of farthest cell invasion from the biopsy border in each of four
quadrants. Sex- and age-matched athymic nude mice were injected with equal numbers of MDA-MB-435, Neo vector-transfected, clone
TH26, or clone TH50 cells to the lateral thigh. Equal sized tumors were excised, and 1-mm3 biopsies were embedded in collagen matrix
with growth medium. After 7 days of incubation, cytospin immunocytochemistry of matrix-invading cells was performed. CD31-positive
staining cells were counted in 10 random high-power fields from each tumor explant and presented as mean ± SD (D). Bovine aortic
endothelial cells were cultured under empty Transwell chambers or chambers that contained parental MDA-MB-435 or clone TH26 cells,
and the BAECs were imaged (E). Results are representative of three independent experiments.
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for 30 minutes to monitor temporal changes in blood oxygenation
and blood flow. Diethylamine NONOate (DEA/NO; 100 nmol/g
body weight) was injected with normal saline through rectal cannula
5.0 minutes after starting the scan. Imaging parameters used were as
follows: T R, 450 milliseconds; flip angle, 45°; number of excitations,
2; slice thickness, 2 mm; matrix size, 64 × 64; number of scans, 30;
total imaging time for the series, 29 minutes.
Laser Doppler Analysis of Tumor and Hindlimb Perfusion
Cr(Cnr)athymic<nu>fBf nude female mice 8 weeks in age were
injected subcutaneously with 106 tumor cells to the lateral thigh.
Doppler analysis of tumor perfusion was performed when tumors
reached 1 cm3 in size. Core temperature was monitored through rec-
tal probe and maintained precisely at 35°C by a heated stage and heat
lamp. Anesthesia was obtained with 1.5% isoflurane. Under loop
magnification, the cutaneous envelope over each tumor was carefully
excised, protecting the vascular network decorating the tumor mass.
A MoorLD1-2λ scanner (Moor Instruments, Devon, UK) was used
with the following parameters: scan area, 1.6 × 2.5 cm; scan speed,
4 msec/pixel; scan time, 1 minutes 54 seconds; override distance,
20 cm. After obtaining baseline tumor perfusion data, animals re-
ceived either 0.05 μg of epinephrine i.p. in sterile warmed saline
or 1 μl/g body weight of a 100-mM stock solution of DEA/NO.
Tumor perfusion was then measured. Perfusion was also determined
in normal hind limbs in sex-, age-, and weight-matched C57BL/6
or athymic mice after DEA/NO administration (1 μl/g weight of a
100-mM stock) using the same anesthetic/physiologic parameters
and imaging conditions.
Intracellular cGMP Assay
Cells were plated at a density 1 × 106 cells/well in 12-well culture
plates (Nunc) in standard medium and weaned over 48 hours of serum
and treated in basal medium + 0.1% BSA with the indicated agents.
Total cGMP was determined through immunoassay (Amersham, GE
Healthcare, UK). In some experiments, equal numbers of MDA-MB-
435, clone TH26, and clone TH50 cells were plated in six-well plates
in standard growth medium and were allowed to adhere for 6 hours;
medium was replaced with serum-free RPMI with 0.1% BSA. Cells
were incubated for 12 hours overnight; conditioned medium was col-
lected, diluted at the indicated concentrations in fresh serum-free
RPMI with 0.1% BSA, applied ± DEA/NO to porcine VSMC; and
cGMP was determined.
Tumor Growth Studies
To confirm growth rates of the cancer cell lines, separate cohorts of
8-week-old female Cr(Cnr)athymic<nu>fBf mice were injected sub-
cutaneously with 106 tumor cells to the lateral thigh. Tumor growth
was measured by the same investigator at twice weekly intervals.
Figure 2. Differential BOLD response and effect of TSP1 in tumor
and normal leg. Anatomic and BOLD MR scans for (A) WT and (B)
TSP1 null mice bearing B16F10 melanoma tumors 1000 mm2 in
size were obtained from T2*-weighted MSME sequences. DEA/
NO (100 nmol/g body weight) was injected with saline through an
intrarectal cannula 5 minutes after starting the scan. Green and red
colors show positive and negative BOLDMRI signals, respectively,
at the indicated times after NO administration. The BOLD images
were superimposed with the corresponding anatomic images to
determine exact locations in the lateral thigh sections. Averaged
BOLDMRI signal changes (C) in tumor and normal leg as a function
of time after NO challenge. The green and red plots show increased
and decreased BOLD MRI signals, respectively. Values are pre-
sented as mean ± SE from five and six experiments in WT and
TSP1 null mice, respectively. Age- and sex-matched C57BL/6 wild
type and TSP1 nullmice underwent laserDoppler analysis of normal
hind limbs (D). After obtaining baseline perfusion data, DEA/NO
(1 μl/g weight of 100-mM stock) was given through rectal bolus.
Data sampling was then done every 2.5 minutes. Results represent
the mean ± SD of four separate animals of each strain.
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Tumor volume was calculated by the formula: volume = W 2 × L/2,
where W = shortest diameter and L = longest diameter. For each cell
line, six mice per group were used.
Tumor Explant Assay
Tumor biopsies that had reached 1 cm3 were harvested from WT,
TSP1 null, and Cr(Cnr)athymic<nu>fBf nude mice and were ex-
planted in type I collagen as described [15]. Explants were incubated
in the presence of DMEM with FCS and the indicated treatment
agents for 7 days, and cell migration through the extracellular matrix
was measured. Results represent the mean ± SD of at least three sep-
arate experiments.
Immunohistochemistry
Tumor explants were prepared as described. On postexplantation
day 7, tumor biopsies were removed from the constructs, and the
collagen gel was digested with type II collagenase (Worthington,
Lakewood, NJ). The mixture was centrifuged, supernatant was aspi-
rated, and cells were resuspended in basal medium without serum.
Cells were attached to charged glass slides (Fisherbrand Superfrost
Slides; Fischer Scientific, Pittsburgh, PA) by cytospinning at 1000 rpm
for 5 minutes and then fixed and rehydrated through 80%, 70%, and
50% alcohol. Slides were rinsed with PBS and then incubated with
3% H2O2 for 30 minutes at room temperature. Sections were then
blocked with 100% normal goat serum in PBS for 30 minutes at room
temperature, washed, and incubated 1 hour with a rat antimouse
monoclonal CD31 antibody (clone MEC 13.3; BD Pharmingen,
Franklin Lakes, NJ) at 1:100 dilution. Slides were washed and incu-
bated with a rat antimouse IgG secondary antibody (ALX-211-052;
Alexis Biochemicals, San Diego, CA) diluted at 1:5000 for 45 minutes,
washed with PBS, and incubated in prediluted streptavidin–HRP con-
jugate (BD Pharmingen) for 45 minutes at room temperature. Color
was developed by DAB substrate kit (BD Pharmingen). Slides were
counterstained using Mayer’s hematoxylin for 2 minutes, dehydrated,
and mounted. CD31-positive cells were counted in 10 randomly se-
lected high-power fields for each tumor explant type.
Endothelial and Tumor Cell Coculture Experiments
Bovine aortic endothelial cells (4 × 104 cells/well) were plated in
24-well culture plates in DMEM + 10% FCS and allowed to reach
confluence. MDA-MB-435 cells or TSP1-transfected MDA-MB-
435 cells (clone TH-26, 5000 cells/well) were plated onto Transwell
inserts (Falcon, Becton Dickinson, NJ) in RPMI 1640 medium and
allowed to adhere. Inserts were then placed in wells containing
BAEC and incubated for 1 week in DMEM at 37°C and 5%
CO2. Bovine aortic endothelial cells were then fixed with 1% glutar-
aldehyde, and images were acquired in phase-contrast illumination
with a microscope (Model IX 70; Olympus, Center Valley, PA).
Statistics
All experiments were replicated at least three times. Results are
presented as mean ± SD with analysis of significance using Student’s
t test or one-way or two-way analysis of variance (ANOVA) with Tu-
key’s post hoc test where indicated using Origin software (version 7;
OriginLab Corp., Northampton, MA), with significance taken at
P values < .05.
Results
Vascular and Tumor-Derived TSP1 Limit Tumor
Angiogenic Responses
Expression of TSP1 either by tumor cells or by the host is known
to limit melanoma tumor growth in mice [40,41]. To assess whether
tumor and host TSP1 differentially regulate NO-stimulated tumor
angiogenic responses, we used a previously published ex vivo assay
that quantifies vascular outgrowth and invasion through a three-
dimensional type I collagen matrix [42]. Explants from B16F10 mel-
anomas grown in wild type and TSP1 null animals were embedded
into three-dimensional type I collagen matrices, and vascular cell in-
vasion and migration through the matrix were quantified (Figure 1A).
Vascular outgrowth was consistently greater in melanoma explants
from TSP1 null animals. Treating with a slow-releasing NO-donor
diethyltriamine NONOate (DETA/NO) enhanced the vascular cell
Figure 3. Differential BOLD response and effect of TSP1 in tumor
and normal leg. Blood oxygen level–dependent MR scans for WT
and TSP1 null mice bearing B16F10 melanoma tumors 1000 mm2
in size were obtained from T2*-weighted MSME sequences. Pos-
itive (A) and negative (B) BOLD MRI signal changes are presented
in tumor and normal leg as a function of time after NO challenge.
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responses to a greater extent in tumor explants from wild type mice
to essentially match that of melanoma explants from TSP1 null mice
(Figure 1A, left panel ). Conversely, addition of exogenous TSP1
suppressed the outgrowth of the melanoma explants from the
TSP1 null mice to match that of explants from wild type mice (Fig-
ure 1A, right panel ).
MDA-MB-435 was previously considered to be a breast carcinoma
cell line but was recently confirmed to be derived from the M14 mel-
anoma cell line [43]. Parental MDA-MB-435 cells express very low
levels of TSP1 [44] and form metastatic tumors with strong angio-
genic potential when grown as xenografts in athymic mice [40].
Growth of the parental cells and TSP1-transfected clones as subcu-
taneous xenografts in Cr(Cnr) nude mice essentially reproduced our
previously published growth curves after mammary fat pad injection
(Figure 1B). TH26 express high levels of intact TSP1 that suppresses
tumor growth, whereas TH50 cells overexpress a C-terminally trun-
cated TSP1 that lacks this activity [40].
Consistent with their in vivo growth rates, tumor explants of these
three clones showed markedly different vascular cell outgrowth in
three-dimensional cultures. Maximum cell outgrowth occurred in
explants of the parental cell line and TH50 clone with minimal en-
hancement by NO (Figure 1C ). A control vector transfectant showed
slightly less vascular outgrowth. In sharp contrast, the TH26 clone
demonstrated no basal vascular cell response and decreased out-
growth after stimulation with exogenous NO (51.3 ± 4.3% less
outgrowth compared to MDA-MB-435 explants). Immunohisto-
chemical detection of endothelial cells by anti-CD31 staining of cy-
tospins recovered from the outgrowths verified that overexpression of
TSP1 in the TH26 explants inhibited endothelial cell outgrowth
(Figure 1D). Thus, TSP1 expressed either in the tumor vasculature
or by the tumor can limit vascular outgrowth in this tumor explant
angiogenesis assay.
Coculture experiments corroborated these findings. Postconfluent
monolayers of BAECs are known to spontaneously form sprouts
and tubes in culture that express characteristic proangiogenic genes
[45]. Quiescent confluent BAECs grown under Transwell chambers
containing MDA-MB-435 cells exposed the BAECs to diffusible fac-
tors secreted by the tumor cells that significantly enhance sprouting
and branching of the BAEC (Figure 1E , center panel ). In contrast,
BAEC exposed to factors released by the TSP1-expressing clone
TH26 cells maintained their quiescent morphology (right panel ), in-
dicating that the level of TSP1 secreted by TH26 cells effectively
Figure 4. Nitric oxide challenge simultaneously decreases MDA-435 tumor blood flow and increases normal tissue blood flow. Age- and
sex-matched athymic nude mice were injected with an MDA-MB-435 tumor cell line to the lateral thigh. When lesions reached 1 cm in
size, laser Doppler analysis of tumor blood flow was performed (A, B). After obtaining baseline perfusion data, therapeutic agents were
given through rectal bolus (DEA/NO 1 μl/g weight of 100-mM stock). Data sampling was then done every 2.5 minutes. Results represent
the mean ± SD of five separate experiments. Representative images are presented. Age- and sex-matched Cr(Cnr) athymic<nu>fBf
mice underwent laser Doppler analysis of normal hind limb perfusion (A, B). After obtaining baseline perfusion data, DEA/NO (1 μl/g
weight of 100-mM stock) was given through rectal bolus. Data sampling was then done every 2.5 minutes. Results represent the mean ±
SD of four separate animals. Representative images are presented. Scale bar, 10 mm.
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blocks the branching and sprouting response stimulated by proangio-
genic factors released by this melanoma cell line.
Endogenous TSP1 in the Tumor Vasculature Does Not Limit
NO-Driven Perfusion in B16F10 Melanoma Tumors
Wild type and TSP1 null mice bearing B16F10 tumors under-
went BOLD MRI to assess acute changes in tumor perfusion in-
duced by systemic NO treatment. Average-intensity analysis of the
BOLD signal integrated over the indicated areas of interest (Figure 2,
A and B) demonstrated the expected net increase in BOLD signal
in normal tissue, with the increase being greater in the TSP1 null
mice (Figure 2C ). In contrast, the average BOLD signal decreased
approximately 5% in the B16F10 tumors of both wild type and
TSP1 null mice (Figure 2C ). This decrease is consistent with de-
creased blood flow into the tumor due to a steal effect resulting from
the peripheral vasodilation by the administered NO. Laser Doppler
analysis of normal hind limb perfusion in C57BL/6 wild type and
TSP1 null mice after an NO challenge confirmed the data obtained
by BOLD MRI (Figure 2D). Increased blood flow was detected in
TSP1 null limbs within 2.5 minutes after administering the NO
donor, and increased flow relative to wild type limbs was maintained
for the duration of measurement.
Further analysis of the BOLD MRI data selecting areas showing
positive versus negative signals confirmed our previous finding in
healthy mouse skeletal muscle that endogenous TSP1 limits the in-
creased BOLD MRI signal in the normal tissue in response to NO
Figure 5. Thrombospondin 1 expression in MDA-MB-435 melanomas tempers vasoactive tumor blood flow responses to vasodilator or
vasopressor challenge. Age- and sex-matched athymic nude mice were injected with equal numbers of either parental MDA-MB-435, clone
TH26, or clone TH50 cells to the lateral thigh. When lesions reached 1 cm in size, laser Doppler analysis of tumor blood flow was performed.
After obtaining baseline perfusion data, therapeutic agents were given [epinephrine, 0.002 μg/g weight through i.p. injection (A, B); DEA/NO,
1 μl/g weight through rectal bolus (C, D)]. Data sampling was then done every 2.5 minutes. Results represent the mean ± SD of five separate
experiments. Representative images are presented. See Movie W2 for a real-time movie of tumor blood flow. Scale bar, 10 mm.
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challenge in areas with positive signal but did not influence those
with negative response (Figure 3A). In the tumors, however, neither
positive nor negative BOLD MRI signals differed between wild type
and TSP1 null mice (Figure 3B). Thus, the Thbs1 genotype of vas-
cular cells recruited into these melanomas does not significantly in-
fluence their acute response to NO, and the net effect of a systemic
NO challenge (Figure 2C ) is to acutely decrease blood oxygen levels
in the tumor secondary to increasing flow in normal peripheral tissue
(Figure 2, C and D; see Movie W1 for a real-time movie of tumor
blood flow).
Tumor TSP1 Limits NO-Stimulated Alterations in Tumor
Blood Flow and Perfusion
Consistent with the results in C57BL/6 mice (Figures 2 and 3),
normal vascular beds in contralateral hind limbs of the athymic mice
demonstrated increased blood flow as determined by laser Doppler
after a vasoactive challenge with exogenous NO (Figure 4, A and B).
To address whether overexpression TSP1 by the tumor can control
tumor blood flow, athymic nude mice were injected with MDA-MB-
435 tumor cells engineered to express variable amounts of TSP1. Pa-
rental MDA-MB-435 cells express very low levels of TSP1 [44]. On
the basis of laser Doppler imaging, epinephrine moderately but rap-
idly increased blood flow in these tumors, which was sustained over
30 minutes (Figure 5, A and B). Relative to the parental tumors, tu-
mors formed by the TSP1 overexpressing clone TH26 demonstrated
attenuated changes in tumor perfusion after vasoactive challenge
using epinephrine (Figure 5, A and B; see Movie W2 for a real-time
movie of tumor blood flow). Epinephrine did not significantly in-
crease blood flow in these tumors. The TH50 clone overexpresses
a C-terminal truncated form of TSP1, lacking residues 1073 to
1152 of the mature protein and shown previously to not inhibit
MDA-MB-435 tumor growth [40]. The epinephrine response of
these tumors was also attenuated relative to the parental cells and re-
turned to baseline by 30 minutes.
Figure 5. (continued)
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Conversely, administering NO tomice bearing parentalMDA-MB-
435 tumors resulted in a rapid 50% decrease in tumor blood flow over
the first 10 minutes that returned toward baseline by 30 minutes (Fig-
ure 5, C and D). Thrombospondin 1-expressing TH26 tumors dem-
onstrated less than half as much decrease in tumor perfusion after
an NO challenge than that seen in parental MDA-MB-435 tumors
with changes persisting over the 30 minutes measuring period. Be-
cause the C-terminal domain of TSP1 is recognized by the CD47 re-
ceptor that mediates its antagonism of NO signaling [36], we also
examined NO responses in these tumors. Tumors formed by TH50
cells exhibited a similar response to NO as the parental MDA-MB-
435 tumors. The immediate decrease in tumor perfusion returned
to baseline by 30 minutes (Figure 5, C and D; see Movie W3 for a
real-time movie of tumor blood flow). Therefore, this truncated TSP1
lacks the ability to functionally limit acute NO responses in vivo.
MDA-MB-435 Tumor Cells Lack NO–cGMP Signaling
A number of human tumors have been reported to have decreased
levels of or lack TSP1 expression [46–49]. Although NO signaling
stimulated by tumor-produced angiogenic factors under such condi-
tions should be increased in vascular cells [15], it is not known
whether NO and TSP1 can similarly regulate cGMP signaling in
tumor cells. Analysis of parental MDA-MB-435 cells and the TH50
and TH26 clones demonstrated no significant change in cGMP levels
after treatment with either exogenous NO or TSP1 (Figure 6A). Analy-
sis of several additional cancer cell lines including B16F10 melanoma,
PC3 prostate carcinoma, and SKOV3 ovarian carcinoma cells demon-
strated a similar lack of NO-cGMP signaling (data not shown). There-
fore, cGMP signaling responses to NO in these tumors are restricted to
the tumor vasculature.
MDA-MB-435 Clone TH26–Conditioned Medium Limits
NO-Driven cGMP Accumulation in VSMC
To assess the ability of the truncated TSP1 secreted by TH50 cells
to regulate vascular cGMP signaling, porcine VSMCs were treated
with conditioned medium from parental MDA-MB-435, TH26,
and TH50 cells. cGMP was quantified after a challenge with 10 μM
DEA/NO. Not surprisingly, the medium from the TSP1-overexpressing
TH26 clone potently blocked an NO-driven cGMP flux (Figure 6B).
Conditioned medium from the parental MDA-MB-435 cells was less
effective at equivalent concentrations for suppressing NO-stimulated
cGMP accumulation in VSMC. The residual inhibition in the paren-
tal cell–conditioned medium may be due to the low level of endog-
enous TSP1 expressed by these cells [44]. Medium obtained from the
TH50 clone did not significantly abrogate an NO-driven flux in
cGMP in VSMC relative to the parental cells, indicating that this
C-terminally truncated TSP1 is a less effective inhibitor of NO/
cGMP signaling.
Discussion
The use of NO and other vasoactive agents for controlling tumor
blood flow remains controversial. Although some evidence indicates
that NO does not acutely and directly alter tumor blood flow
[2,5,50], others have reported a diminution of tumor blood flow
after NO synthase inhibition in vivo [19,20,50–54]. Conversely, in-
creased tumor blood flow has been noted with exogenous NO ad-
ministration [17,51]. Some of these disparities may be attributed
to variations in imaging modalities and techniques, vasoactive agents
used, and the specific tumor models. We used two distinct and com-
plementary noninvasive imaging modalities, BOLD MRI and laser
Doppler, which are highly reproducible in both animals and people.
Analysis of a syngeneic murine melanoma (B16F10) and a human
xenograft melanoma (MDA-MB-435) demonstrate that NO does
not show significant vasodilator activity for the tumor vasculature.
Regardless of murine strain or tumor cell line studied, administration
of exogenous NO resulted in a rapid decrease in tumor blood flow as
documented by both BOLD MRI and laser Doppler. Decreased
blood flow in the abnormal vascular network of the tumor was par-
alleled by a concurrent increase in blood flow in adjacent and distant
normal vascular networks (Figures 2C , 3A, and 4, A and B), estab-
lishing that NO drives a redistribution of blood away from the tumor
Figure 6. MDA-MB-435 melanoma cells do not demonstrate NO-
or TSP1-sensitive cGMP signaling. MDA-MB-435, clone TH26, and
clone TH50 tumor cells (2.5 × 104/well) were plated in RPMI and
allowed to adhere for 12 hours. The next day, cells were incubated
for 2.5 minutes in basal medium (lacking serum) ± DETA/NO
(10 μM) ± TSP1 (2.2 nM), and cGMP levels were determined by
immunoassay (A). Results represent the mean ± SD of three
separate experiments. Porcine femoral artery VSMCs were plated
(2.5 × 104/well) in 12-well plates in growth medium, weaned of
serum over 48 hours, incubated in the indicated concentrations
of tumor-conditioned medium (0.01–1% in basal smooth muscle
medium + 0.1% BSA) for 15 minutes, and DEA/NO (10 μM) was
added for 2.5 minutes. Cells were lysed and cGMP determined
through ELISA (B). Results presented are representative of three
separate experiments.
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vessels through active dilation of normal vascular networks through a
steal effect. Conversely, constriction of peripheral vasculature using
epinephrine acutely increased blood flow into these tumors, presum-
ably by increasing the mean pressure in arteries supplying the tumor.
Therefore, the tumor behaves in both cases as a passive resistance
whose flow is inversely related to that in the host periphery.
The presence of TSP1 in the tumor vasculature and surrounding
normal tissues of the host animal had minimal effects on acute reg-
ulation of tumor blood flow. In contrast, overexpression of TSP1 by
the tumor cells significantly attenuated blood flow changes after NO
treatment (Figure 5, C and D), supporting a role for TSP1 in mod-
ulating tumor blood flow responses. Intravenous treatment with the
type 1 repeats of TSP1 was inferred to alter blood flow in pancreatic
tumors [39]. Assessed by intravenous injection of fluorescein-labeled
dextran and histologic analysis of excised tumors, treated animals
had decreased total vessel area and less fluorescence signal in CD31-
positive vessels. Although suggesting a decrease in vessel filling and
blood flow, these findings may represent primarily a loss of perfused
vessels rather than a change in flow, which was not directly assessed.
The type 1 repeats can block NO signaling in vascular cells through
CD36 [15,55], but our previous studies in ischemic injury models in-
dicate that CD36 signaling does not significantly contribute to
acute regulation of blood flow [38]. Thus, the antitumor activity of
TSP1-based drugs targeting CD36 may occur exclusively through in-
hibiting angiogenesis rather than flow, the latter being controlled
through CD47.
At the cellular level, vascular cells are the major target for this acute
activity of NO in tumors because most tumor cells do not demon-
strate NO-driven cyclic nucleotide signaling. MDA-MB-435 cells
and clones from the same parent did not demonstrate an accumula-
tion of intracellular cGMP after treatment with NO. This lack of
response is not unique to MDA-MB-435 cells. Several other com-
mon tumor cell lines including B16F10, PC3, and SKOV3 cells
failed to demonstrate a cGMP flux after NO treatment (data not
shown). Tumor blood vessels have also been found incapable of pro-
ducing NO in response to acetylcholine [56]. Thus, tumors generally
lack NO-responsive cGMP signaling.
Consistent with our data, increased tumor blood flow has been
found in animal models after challenge with one [3,57,58] or more
vasoconstrictors [59] alone or in combination with β-blockers such
as propranolol [60]. The same response has been confirmed in pa-
tients [32,61]. However, the increased tumor perfusion induced by
systemic treatment with vasoconstrictors was relatively brief. Pro-
longed increases in tumor blood flow could only be achieved through
continuous infusion of the vasoconstrictor [3]. In a xenograft soft
tissue tumor model, we found moderate enhancement of tumor
blood flow after a single i.p. dose of epinephrine. As with NO, blood
flow changes to epinephrine were tempered in tumors that overex-
press TSP1. In all cases, tumor blood flow tended to return to base-
line within 30 minutes. Although similar agents can modify tumor
blood flow in people, their use may be limited by increases in heart
rate and blood pressure [61].
Tumor blood flow, therefore, is a passive response to alterations in
flow and resistance in the nontumor vascular networks and system of
the host both regionally and centrally. If vascular resistance beyond
the tumor decreases, as with administration of exogenous NO, blood
rapidly drains from the tumor. Alternatively, increasing peripheral vas-
cular resistance in normal vascular networks with a centrally acting
hypertensive agent redistributes blood into the tumor vasculature.
Acutely, the tumor vasculature is resistant to vasoactive challenge
and registers no direct response.
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Movie W1. Syngeneic B16 melanoma perfusion responses to NO in wild type versus TSP1 null mice. Each movie shows an initial light
image followed by a pretreatment Doppler image and a time lapse movie (500 milliseconds = 2.5 minutes) of Doppler scans taken over
30 min after administration of DEA/NO as a rectal bolus.
Movie W2. Perfusion responses toNO in aM14 (MDA-MB-435) humanmelanoma xenograft overexpressing full-length thrombospondin-1
(clone TH26). Time lapsemovies (500milliseconds= 2.5minutes) of Doppler scans taken over 30min after administration of DEA/NO as a
rectal bolus.
Movie W3. Perfusion responses to NO in a M14 (MDA-MB-435) human melanoma xenograft overexpressing C-terminal–truncated
thrombospondin-1 (clone TH50). Time lapse movie (500 milliseconds = 5 minutes) of Doppler scans taken over 40 min after adminis-
tration of DEA/NO as a rectal bolus.
